Status:
UNKNOWN
Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis
Lead Sponsor:
China Medical University Hospital
Collaborating Sponsors:
Ministry of Health and Welfare, Taiwan
Conditions:
Hepatocellular Carcinoma Recurrent
Surgery
Eligibility:
All Genders
20+ years
Brief Summary
Backgrounds: Surgeries are the mainstream of curative therapies for hepatocellular carcinoma (HCC). However, high risk of recurrent HCC after liver surgeries is still the unsolved clinical issue (earl...
Detailed Description
Study subject and methods: Nationwide retrospective cohort study 1. Establish prediction models for postoperative recurrent HCC by analyzing surgical HCC patients' clinical information and periopera...
Eligibility Criteria
Inclusion
- All HCC surgical patients aged more than 20 year-old who sign informed consent for donating remnant tissue or blood after liver surgeries
Exclusion
- Pregnant women
Key Trial Info
Start Date :
April 22 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
800 Patients enrolled
Trial Details
Trial ID
NCT05990959
Start Date
April 22 2022
End Date
December 31 2025
Last Update
August 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital, Department of Surgery
Taichung, Taiwan, 404